论文部分内容阅读
目的观察辛伐他汀对急性心肌梗死(AMI)患者血清高敏C-反应蛋白(hs-CRP)、内皮素-1(ET-1)、心肌肌酸激酶同功酶(CK-MB)的影响,探讨辛伐他汀在斑块稳定性和炎症反应中的作用。方法选取AMI患者56例,按发病前是否因心绞痛、血脂异常服用过辛伐他汀分为治疗组25例,服用辛伐他汀(20mg,1次/d)4周以上与对照组31例,未服用辛伐他汀。采用放射免疫法、酶联免疫吸附法检测2组患者血清hs-CRP、ET-1、CK-MB水平。结果治疗组血浆hs-CRP、ET-1、CK-MB水平低于对照组,差异有统计学意义(P<0.05)。结论辛伐他汀可抑制炎症反应,改善内皮功能,稳定粥样斑块,缩小心肌梗死范围。
Objective To observe the effect of simvastatin on serum high sensitive C-reactive protein (hs-CRP), endothelin-1 (ET-1) and myocardial creatine kinase isoenzyme (CK- MB) in patients with acute myocardial infarction (AMI) To investigate the role of simvastatin in plaque stability and inflammatory response. Methods Fifty-six patients with acute myocardial infarction (AMI) were divided into treatment group (n = 25) treated with Simvastatin (angina pectoris and dyslipidemia) before treatment, and simvastatin (20 mg once daily for 4 weeks) and control group Take simvastatin. Serum hs-CRP, ET-1 and CK-MB levels were measured by radioimmunoassay and enzyme-linked immunosorbent assay. Results The plasma levels of hs-CRP, ET-1 and CK-MB in the treatment group were lower than those in the control group, with significant difference (P <0.05). Conclusion Simvastatin can inhibit the inflammatory reaction, improve endothelial function, stabilize atherosclerotic plaque and reduce the range of myocardial infarction.